BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35490227)

  • 1. Machine learning algorithms to estimate 10-Year survival in patients with bone metastases due to prostate cancer: toward a disease-specific survival estimation tool.
    Anderson AB; Grazal C; Wedin R; Kuo C; Chen Y; Christensen BR; Cullen J; Forsberg JA
    BMC Cancer; 2022 Apr; 22(1):476. PubMed ID: 35490227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Validation of PATHFx Version 3.0 in Patients Treated Surgically and Nonsurgically for Symptomatic Skeletal Metastases.
    Anderson AB; Wedin R; Fabbri N; Boland P; Healey J; Forsberg JA
    Clin Orthop Relat Res; 2020 Apr; 478(4):808-818. PubMed ID: 32195761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?
    Pan YT; Lin YP; Yen HK; Yen HH; Huang CC; Hsieh HC; Janssen S; Hu MH; Lin WH; Groot OQ
    Clin Orthop Relat Res; 2024 Mar; ():. PubMed ID: 38517402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the SORG Machine-learning Algorithm for Extremity Metastases Generalize to a Contemporary Cohort of Patients? Temporal Validation From 2016 to 2020.
    de Groot TM; Ramsey D; Groot OQ; Fourman M; Karhade AV; Twining PK; Berner EA; Fenn BP; Collins AK; Raskin K; Lozano S; Newman E; Ferrone M; Doornberg JN; Schwab JH
    Clin Orthop Relat Res; 2023 Dec; 481(12):2419-2430. PubMed ID: 37229565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can A Multivariate Model for Survival Estimation in Skeletal Metastases (PATHFx) Be Externally Validated Using Japanese Patients?
    Ogura K; Gokita T; Shinoda Y; Kawano H; Takagi T; Ae K; Kawai A; Wedin R; Forsberg JA
    Clin Orthop Relat Res; 2017 Sep; 475(9):2263-2270. PubMed ID: 28560532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
    Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
    Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can We Estimate Short- and Intermediate-term Survival in Patients Undergoing Surgery for Metastatic Bone Disease?
    Forsberg JA; Wedin R; Boland PJ; Healey JH
    Clin Orthop Relat Res; 2017 Apr; 475(4):1252-1261. PubMed ID: 27909972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
    Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
    Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the SORG Algorithm Predict 5-year Survival in Patients with Chondrosarcoma? An External Validation.
    Bongers MER; Thio QCBS; Karhade AV; Stor ML; Raskin KA; Lozano Calderon SA; DeLaney TF; Ferrone ML; Schwab JH
    Clin Orthop Relat Res; 2019 Oct; 477(10):2296-2303. PubMed ID: 31107338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Internal Validation of Machine Learning Algorithms for Preoperative Survival Prediction of Extremity Metastatic Disease.
    Thio QCBS; Karhade AV; Bindels BJJ; Ogink PT; Bramer JAM; Ferrone ML; Calderón SL; Raskin KA; Schwab JH
    Clin Orthop Relat Res; 2020 Feb; 478(2):322-333. PubMed ID: 31651589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External Validation and Optimization of the SPRING Model for Prediction of Survival After Surgical Treatment of Bone Metastases of the Extremities.
    Sørensen MS; Gerds TA; Hindsø K; Petersen MM
    Clin Orthop Relat Res; 2018 Aug; 476(8):1591-1599. PubMed ID: 30020148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model.
    Perera M; Smith L; Thompson I; Breemer G; Papa N; Patel MI; Swindle P; Smith E
    Eur Urol Focus; 2022 Sep; 8(5):1204-1210. PubMed ID: 34920976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease-decision analysis and comparison of three international patient populations.
    Piccioli A; Spinelli MS; Forsberg JA; Wedin R; Healey JH; Ippolito V; Daolio PA; Ruggieri P; Maccauro G; Gasbarrini A; Biagini R; Piana R; Fazioli F; Luzzati A; Di Martino A; Nicolosi F; Camnasio F; Rosa MA; Campanacci DA; Denaro V; Capanna R
    BMC Cancer; 2015 May; 15():424. PubMed ID: 25998535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
    Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
    J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of PATHFx 2.0: An open-source tool for estimating survival in patients undergoing pathologic fracture fixation.
    Overmann AL; Clark DM; Tsagkozis P; Wedin R; Forsberg JA
    J Orthop Res; 2020 Oct; 38(10):2149-2156. PubMed ID: 32492213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review.
    Pinart M; Kunath F; Lieb V; Tsaur I; Wullich B; Schmidt S;
    World J Urol; 2020 Mar; 38(3):613-635. PubMed ID: 30554274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.